Contrasting CardioGenics (OTCMKTS:CGNH) & Veracyte (NASDAQ:VCYT)

CardioGenics (OTCMKTS:CGNH) and Veracyte (NASDAQ:VCYT) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, institutional ownership, earnings, valuation, dividends, analyst recommendations and risk.

Earnings and Valuation

This table compares CardioGenics and Veracyte”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CardioGenics	N/A	N/A	N/A	N/A	N/A
Veracyte	$517.15 million	7.58	$66.35 million	$1.09	45.09

Veracyte has higher revenue and earnings than CardioGenics.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for CardioGenics and Veracyte, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CardioGenics	0	0	0	0	0.00
Veracyte	1	3	4	1	2.56

Veracyte has a consensus price target of $47.57, suggesting a potential downside of 3.21%. Given CardioGenics’ higher possible upside, equities analysts plainly believe CardioGenics is more favorable than Veracyte.

Profitability

This table compares CardioGenics and Veracyte’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
CardioGenics	N/A	N/A	N/A
Veracyte	16.25%	9.07%	8.38%

Summary

Veracyte beats CardioGenics on 7 of the 8 factors compared between the two stocks.

About CardioGenics

CardioGenics Holdings Inc. engages in the development and commercialization of diagnostic test products for the in vitro diagnostics testing market in the United States, Canada, Europe, and internationally. Its products include QL Care Analyzer, a portable, stand-alone, and automated point-of-care (POC) immunoassay analyzer that uses a proprietary self-metering cartridge to perform immunoassay tests at the POC; a series of immunoassay tests to identify cardiac markers in the blood at the time of a heart attack; and paramagnetic beads that are used as solid surfaces in heterogeneous immunoassay tests by clinical and research laboratories. The company was formerly known as Jag Media Holdings, Inc. and changed its name to CardioGenics Holdings Inc. in 2009. The company was founded in 1997 and is headquartered in Mississauga, Canada.

About Veracyte

Veracyte, Inc. engages in the research, development and commercialization of diagnostic products. The firm’s portfolio includes Afirma, Percepta, and Envisia. It intends to treat thyroid cancer, improve lung cancer screening, and clarify the diagnosis of idiopathic pulmonary fibrosis. The company was founded by Bonnie H. Anderson and Y. Douglas Dolginow on August 15, 2006 and is headquartered in South San Francisco, CA.